| Project/Area Number |
24791724
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 卵巣明細胞腺癌 / mTOR / HIF-1 / mTOR阻害剤 / everolimus / 治療の個別化 / 婦人科腫瘍学 / 婦人科病理学 / 癌の微小環境 / Everolimus |
|---|
| Research Abstract |
(1) The mTOR inhibitor (Everolimus) of the mTOR - HIF-1 pathway restrained it. evelorimus provided suppression of the cellular proliferative capacity and promotion of degradation pathway (VHL) of HIF-1. As for this drug, the likelihood as a new therapeutic drug through the mTOR - HIF-1 pathway in the ovarian clear cell adenocarcinoma was expected.
(2) The effect of treatment in vivo showed antitumor effect more in Everolimus + CDDP group than an Everolimus single group.
(3) As a treatment marker of the clear cell adenocarcinoma, expression patterns of HIF-1, a positive rate of p-mTOR may be effective.
|
